Advent to sell generic unit to PE firm GTCR for US$ 4.8 billion; Novo shapes up for obesity race by cutting 9,000 jobs
In this week’s news, Advent International has agreed to sell the Czech generic drugmaker Zentiva to private equity firm G...
Impressions : 1215
Trump withdraws US from WHO; Novo’s Ozempic, Wegovy among 15 new drugs chosen for price negotiations under IRA
On the day Donald Trump was sworn in as the 47th President of the United States, there was a deluge of some 200 measures, which...
Impressions : 1891
Astra’s cancer drugs impress at ASCO; Moderna’s mRESVIA becomes first mRNA RSV vaccine approved by FDA
This week saw the American Society of Clinical Oncology (ASCO) annual meeting in Chicago where cancer researchers presented det...
Impressions : 1233
Vertex buys Alpine Immune Sciences for US$ 4.9 billion; Merck KGaA signs ADC deal with AI biotech Caris
This week’s Phispers comes packed with deals, approvals and trial wins. Vertex Pharmaceuticals has decided to bet big on ...
Impressions : 2109
Big pharma slash prices for China’s insurance scheme; plan major investments in gene therapy
This week, Phispers brings you news on 11 large multinational drugmakers, including Pfizer and Novartis, that have set aside US...
Impressions : 2182
Insys founder Kapoor convicted in opioid scandal; FDA rules changing due to new technologies
This week, Phispers brings you news about John Kapoor, the founder of Insys who was found guilty of engaging in a bribery schem...
Impressions : 3739
Sanofi and AbbVie CEOs suffer pay cuts, FDA Warning Letters to Pfizer, Jubilant’s Indian operations
This week, Phispers brings you news about two antidepressants — J&J’s esketamine and Allergan’s rapastine...
Impressions : 3610
PhRMA publishes list of US cancer drug pipeline; Biocon-Mylan’s Neulasta biosim bags FDA nod
This week in Phispers, Biocon–Mylan scored a big win by getting the FDA nod for its biosimilar to Amgen’s Neulasta....
Impressions : 2475
Takeda to buy Shire for US$ 65 billion; Fresenius dumps Akorn over data-integrity concerns
PharmaCompass has maintained that 2018 would be the year of M&As. This week’s Phispers only reaffirms our conviction ...
Impressions : 3496
Novartis buys gene therapy for US$ 8.7 billion; France to target healthcare for its AI strategy
This week in
Phispers, we have some good and bad news on Swiss drugmaker, Novartis. While it acquired gene-therapy company AveX...
Impressions : 4384
China sees sharp rise in U.S. generic approvals; GSK opts out of Pfizer’s OTC business race
This week,
Phispers brings you news on Pfizer’s OTC auction. After Reckitt Benckiser, even GSK opted out of the race, le...
Impressions : 3738
Novartis considering a sale of Sandoz’s oral solids business; Sanofi’s dengue vaccine found to make disease worse
This week, Phispers brings you news on the biggest M&A deal of 2017 — the acquisition of health insurer Aetna by phar...
Impressions : 3840
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.